Ooe Kazuhiro

オオエカズヒロ | Ooe Kazuhiro

Affiliation and department：
Research theme for competitive and other funds (8)：

2024 - 2027 Development of innovative alpha therapy targeting cancer-associated fibroblasts
2022 - 2025 加速器製造可能な新規セラノスティクス核種の開発
2022 - 2025 悪性黒色腫の標的α線治療を指向するAt-211標識薬剤開発
2019 - 2022 Development of At-211-labeled agents targeting the tumor hypoxia region
2019 - 2022 Development of accelerator produced radionuclides for radioisotope therapy application

Show all

Papers (84)：

Kaori Abe, Tadashi Watabe, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, Sadahiro Naka, Kazuhiro Ooe, Atsushi Toyoshima, Frederik Giesel, Takeshi Usui, et al. Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models. International journal of molecular sciences. 2024. 25. 21
Tadashi Watabe, Kazuko Kaneda-Nakashima, Yuichiro Kadonaga, Kazuhiro Ooe, Thosapol Sampunta, Naoki Hirose, Xiaojie Yin, Hiromitsu Haba, Yukiyoshi Kon, Atsushi Toyoshima, et al. Preclinical Evaluation of Biodistribution and Toxicity of [211At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer. International journal of molecular sciences. 2024. 25. 11
Sadahiro Naka, Kazuhiro Ooe, Yoshifumi Shirakami, Kenta Kurimoto, Toshihiro Sakai, Kazuhiro Takahashi, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Hiroki Kato, et al. Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial. EJNMMI radiopharmacy and chemistry. 2024. 9. 1. 29-29
Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe, Kazuhiro Ooe, Atsushi Toyoshima, Kazuhiro Takahashi, Koichi Sawada, Takashi Iimori, Yoshitada Masuda, Takashi Uno, et al. Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics. EJNMMI radiopharmacy and chemistry. 2024. 9. 1. 17-17
Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, Tadashi Watabe, Kazuhiro Ooe, Xiaojie Yin, Hiromitsu Haba, Kenji Shirasaki, Hidetoshi Kikunaga, Kazuaki Tsukada, et al. Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides. International Journal of Molecular Sciences. 2024. 25. 2. 933-933

ｍore...

MISC (38)：

島本博彰, 加藤弘樹, 片山大輔, 角永悠一郎, 大江一弘, HUANG Xuhao, 下山敦史, 下山敦史, 樺山一哉, 樺山一哉, et al. Intratumoral administration of astatine-211-labeled gold nanoparticles for alpha-particle therapy: Antitumor effect for a mouse model of tongue cancer. 歯科放射線. 2024. 64
大江一弘, 吉村崇. Analysis of iodine with a capillary electrophoresis method for speciation of astatine. 日本放射化学会討論会(Web). 2023. 67th
HUANG Xuhao, 加藤弘樹, 角永悠一郎, 下山敦史, 樺山一哉, 片山大輔, 大江一弘, 豊嶋厚史, 羽場宏光, WANG Yang, et al. Synthesis and Evaluation of At-211 Labeled Gold Nanoparticles for Alpha Brachytherapy. 日本放射化学会討論会(Web). 2021. 65th
加藤弘樹, 片山大輔, 大江一弘, 角永悠一郎, 黄栩昊, 下山敦史, 樺山一哉, 深瀬浩一, 畑澤順. 局所投与による癌増殖抑制のためのアスタチン標識金ナノ粒子の最適化. 核医学(Web). 2021. 58. Supplement
片山大輔, 加藤弘樹, 大江一弘, 角永悠一郎, 黄栩昊, 下山敦史, 樺山一哉, 深瀬浩一, 畑澤順. アスタチン-211標識金ナノ粒子局所投与による癌増殖抑制. 核医学(Web). 2021. 58. Supplement

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page